you can read marschalek's preprint submission to bioRxiv here:<p><a href="https://www.biorxiv.org/content/10.1101/2021.04.27.441606v1" rel="nofollow">https://www.biorxiv.org/content/10.1101/2021.04.27.441606v1</a><p>in this case work is with transposition of genetic elements toward examination of the cellular dynamics of covid infection.<p>a search of bioRxiv for rolf marschalek yeilds 1 submissions bearing his name as a co-author.<p>at face value this is still in the realm of hypothesis rather than thesis.<p>[ADNDM]
a related pronouncement, and revelation.<p>>>For Vaxzevria, Greinacher and his collaborator Rolf Marschalek, a molecular biologist at Frankfurt University, are calling for tests of a simple solution: halving the dose. In AstraZeneca's phase 3 trial in the United Kingdom, a small number of people accidentally received a lower dose and had fewer side effects in general; perhaps a reduced dose is also less likely to trigger the kind of strong inflammation that boosts PF4 antibodies, the researchers say. And unexpectedly, those people were slightly better protected, perhaps because high levels of inflammation can actually block the formation of antibodies. “Part of the problem might be that they just overdose” the vaccine, Greinacher says.<<<p>to wit, currently accepted dosage of vaccine may be problematic.<p>also Grienacher and marschalek share a collaboration so there is a further lead to the entirety of this story.